COUR Pharmaceuticals is pioneering a novel approach to treating autoimmune diseases through its proprietary nanoparticle platform. This technology is designed to reprogram the immune system to achieve antigen-specific tolerance, effectively addressing the root causes of immune-mediated diseases rather than merely alleviating symptoms. The platform utilizes biodegradable nanoparticles that encapsulate specific antigens, which, upon infusion, bind to immune cells and facilitate the targeted delivery of these antigens to the spleen and liver. This process promotes the induction of tolerance by allowing the immune system to recognize these antigens as self, thereby reducing harmful immune responses.

The lead product from COUR's nanoparticle platform, CNP-101 (also known as TAK-101), targets celiac disease and has demonstrated the ability to induce antigen-specific immune tolerance in clinical trials. This innovative approach has shown promise in reducing inflammation and protecting the intestines from gluten-related damage. Additionally, COUR is advancing other investigational therapies, such as CNP-106 for Myasthenia Gravis and CNP-104 for Primary Biliary Cholangitis, which also aim to reprogram the immune response to prevent disease progression. Overall, COUR Pharmaceuticals' technology represents a significant advancement in the treatment of autoimmune conditions by harnessing the immune system's inherent regulatory mechanisms.

United States

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

COUR Pharmaceuticals

Company Details